Somjorn Phatthanan, Kamanamool Nanticha, Kanokrungsee Silada, Rojhirunsakool Salinee, Udompataikul Montree
Skin Center, Srinakharinwirot University, Bangkok, Thailand.
Department of Preventive and Social Medicine, Srinakharinwirot University, Bangkok, Thailand.
Asian Pac J Allergy Immunol. 2024 Dec;42(4):361-367. doi: 10.12932/AP-230920-0969.
Nowadays, moisturizers contain non-steroidal anti-inflammatory agents that help for treatment of atopic dermatitis (AD). Defensil® (black currant seed oil, sunflower oil, and balloon vine), a new anti-inflammatory, obtained from plant extracts, remain had a few studies for AD.
To compare the effectiveness of moisturizer containing 3% Defensil®, 5% dexpanthenol and ceramide (LDC) with 5% urea cream in childhood AD treatment.
Thirty-eight patients with diagnosis of atopic dermatitis by UK working party's criteria were recruited in randomized, controlled, double-blinded 4-week study. The patients were received with twice-daily application of LDC cream on one side of the body and 5% urea cream on the opposite side. The clinical severity was assessed by modified scoring of atopic dermatitis (SCORAD). Median time to remission was analyzed by survival analysis.
Thirty-seven out of 38 patients accomplished the protocol. The clinical SCORAD significantly improved from baseline in both groups (p < 0.001) after 2 and 4 weeks. Furthermore, the LDC group significantly reduced severity of disease better than the 5% urea group (P = 0.043). The mean difference SCORAD scores were -13.83 (±1.83) and -13.04 (±3.22) respectively. Stratum corneum hydration (SCH) was enhanced from baseline in both groups (p < 0.001) but no statistically significant difference between both groups. Median time to remission had no statistically significant difference (P = 0.697).
The effectiveness of LDC cream is better than 5% urea cream for improving clinical atopic dermatitis. It was suggested that moisturizer containing LDC could be used for the treatment of mild-to-moderate childhood atopic dermatitis.
如今,保湿剂含有有助于治疗特应性皮炎(AD)的非甾体抗炎药。Defensil®(黑加仑籽油、向日葵油和倒地铃)是一种从植物提取物中获得的新型抗炎剂,针对AD的研究较少。
比较含3%Defensil®、5%泛醇和神经酰胺的保湿剂(LDC)与5%尿素乳膏治疗儿童AD的效果。
根据英国工作组标准诊断为特应性皮炎的38例患者被纳入一项随机、对照、双盲的4周研究。患者身体一侧每日两次涂抹LDC乳膏,另一侧涂抹5%尿素乳膏。通过改良的特应性皮炎评分(SCORAD)评估临床严重程度。通过生存分析分析缓解的中位时间。
38例患者中有37例完成了方案。两组在2周和4周后临床SCORAD均较基线显著改善(p<0.001)。此外,LDC组疾病严重程度的降低明显优于5%尿素组(P=0.043)。SCORAD评分的平均差异分别为-13.83(±1.83)和-13.04(±3.22)。两组角质层水合作用(SCH)均较基线增强(p<0.001),但两组间无统计学显著差异。缓解的中位时间无统计学显著差异(P=0.697)。
LDC乳膏在改善临床特应性皮炎方面的效果优于5%尿素乳膏。建议含LDC的保湿剂可用于治疗轻度至中度儿童特应性皮炎。